Every year, a significant number of Abbreviated New Drug Applications submitted to the United States Food and Drug Administration face Refuse to Receive decisions, major deficiency letters, or prolonged review cycles, not because the science is flawed, but because the dossier is incomplete, the justifications are weak, or the documentation fails to meet the standard that the Division of Filing Review within the Office of Generic Drugs has set. For regulatory professionals at every level, from junior associates to directors and vice presidents overseeing global submissions, understanding what FDA truly expects during filing review is not optional knowledge. It is foundational.
At the Generic Drugs Forum held on April 22, 2026, Truong-Vinh (Vinh) Phung, PharmD, Commander of the US Public Health Service and Regulatory Officer at the Division of Filing Review (DFR), Office of Generic Drugs, CDER, US FDA, presented a landmark discussion titled "Proactive Strategies to Avoid Major Filing Deficiencies and Other Stumbling Blocks." The insights shared in that forum crystallize years of FDA review experience into actionable guidance. This article unpacks those insights, expands upon them with regulatory depth, and offers a complete professional framework for anyone involved in ANDA preparation, submission strategy, or quality oversight.
Understanding the Filing Review Process: What Happens When Your ANDA Lands at FDA
Before diving into deficiencies, regulatory professionals must understand the architecture of ANDA review at FDA. When an ANDA is submitted electronically through the Electronic Submissions Gateway, it first enters the Division of Filing Review, not the full scientific review team. The DFR conducts a completeness assessment, essentially checking whether the application contains all the elements required under 21 CFR 314.94 and whether the submission is sufficiently complete to permit a substantive review.
This is the Refuse to File (also called Refuse to Receive or RTR) checkpoint. If the DFR determines that the application is not sufficiently complete, FDA refuses to receive it within 60 days of submission under PDUFA timelines. This wastes months of preparation time, delays market entry, and signals to the broader review team that the applicant may not be ready for rigorous engagement.
The RTR decision is not a scientific judgment on the merits of the drug. It is an administrative and technical gatekeeping function. However, crossing this threshold cleanly requires scientific rigor, documentation completeness, and an intimate understanding of what FDA considers sufficient upfront.
The Most Common Filing Deficiencies and Why They Keep Happening
1. Missing Bioequivalence (BE) Data or Inadequate BE Study Design
Bioequivalence is the scientific and regulatory cornerstone of any ANDA. The fundamental premise of generic drug approval under the Hatch-Waxman Act is that a generic product is therapeutically equivalent to the Reference Listed Drug (RLD), which means it must demonstrate pharmacokinetic equivalence within the 80 to 125 percent confidence interval boundaries for AUC and Cmax under fasting and/or fed conditions, as specified in FDA's product-specific guidance (PSG).
Major BE-related filing deficiencies include:
Submitting without a complete BE study: Some applicants submit ANDAs with BE studies that are ongoing or with only partial data, assuming FDA will allow the data to be submitted later. This is almost always a recipe for RTR or a major deficiency.
Failure to follow product specific guidance: FDA publishes PSGs for hundreds of drug products, specifying the recommended study design (fasting, fed, or both), strength justification requirements, dissolution testing requirements, and in some cases, in vitro permeation test (IVPT) data requirements for topical products. Ignoring or deviating from PSG without adequate scientific justification is one of the single most common filing failures.
Inadequate waiver justifications for BCS based biowaivers: If an applicant is requesting a biowaiver under the Biopharmaceutics Classification System (BCS), the waiver must be scientifically justified with solubility data across the physiological pH range, permeability classification, dissolution data meeting the 85 percent in 30 minutes criterion, and excipient analysis. Weak or incomplete biowaiver packages are flagged immediately.
Bioinequivalence in the study submitted: Paradoxically, some applications contain BE studies that already demonstrate bioinequivalence but are still submitted, presumably hoping the review team will overlook the data. This is both scientifically and professionally untenable.
For Director Level Consideration: At the strategic level, BE study design decisions should be made at least 24 to 36 months before the anticipated submission date. This requires early engagement with FDA through the controlled correspondence mechanism under GDUFA, using it proactively to seek scientific feedback on study design before spending millions on a pivotal BE study.
2. Missing or Incomplete Stability Data
Stability data is the backbone of Module 3.2.P.8 in the eCTD structure. For an ANDA, FDA requires stability data that demonstrates the product maintains its quality attributes (assay, degradation products, dissolution, physical characteristics) throughout the proposed shelf life under ICH Q1A(R2) conditions, primarily 25 degrees Celsius and 60 percent relative humidity for long-term data and 40 degrees Celsius and 75 percent relative humidity for accelerated data, with intermediate conditions where applicable.
Filing deficiencies related to stability commonly arise because:
Only accelerated data is available at the time of submission: While FDA does accept submissions with accelerated stability data to support a tentative shelf life, the data package must be scientifically sound, the container closure system must be fully characterized, and the applicant must commit to providing long-term data as it becomes available.
Stability studies not conducted on the commercial-scale batch or final formulation: Stability studies conducted on pilot-scale or non-representative batches, or on formulations that differ from the final proposed commercial formula, are not acceptable. FDA expects stability data from batches that mirror the commercial manufacturing process.
Missing primary packaging information: Stability is intimately linked to the container closure system. Applications that omit container closure system data, extractable and leachable studies where relevant, and moisture vapor transmission rate data for moisture-sensitive products will be flagged.
Incomplete photostability data: ICH Q1B photostability testing is frequently overlooked, particularly for solid oral dosage forms that may be sensitive to light.
Stability data gaps for multiple strengths: If an ANDA covers multiple strengths, each strength must have its own stability commitment and supporting data, unless a bracketing or matrixing design is employed and scientifically justified under ICH Q1D.
3. Incomplete Drug Master File (DMF) References or Module 3 Gaps
The Drug Master File (DMF) system allows API manufacturers to protect their proprietary information while giving FDA access to critical drug substance data. For ANDA applicants who reference an API DMF, the DMF must be active, complete, and authorized for reference.
Common DMF-related filing gaps include:
Authorization letter not submitted or expired: The Letter of Authorization (LOA) from the DMF holder to the ANDA applicant must be included in the application and must be current.
DMF not updated to reflect current manufacturing process: If the API manufacturer has changed synthetic routes, starting materials, or specification limits without updating the DMF, the ANDA referencing that DMF will carry the discrepancy forward, creating a major gap during review.
Incomplete Module 3.2.S sections within the ANDA: Even when a DMF is referenced, the applicant must provide its own drug substance characterization data, specification justification, and where applicable, ICH M7 assessments for mutagenic impurities. Applications that rely entirely on the DMF without completing their own Module 3.2.S documentation are routinely deficient.
Module 3.2.P gaps for drug product: Common Module 3 product gaps include missing pharmaceutical development reports (3.2.P.2), incomplete process validation data (3.2.P.3.5), and absent or inadequate analytical method validation summaries (3.2.P.5.3).
For Director Level Consideration: Organizations that frequently reference external DMFs should establish a vendor qualification and DMF monitoring program that tracks DMF annual report submission status, responds quickly to FDA information requests to DMF holders, and maintains direct communication with API vendors about any planned changes that would require DMF amendments.
4. Weak, Missing, or Internally Inconsistent Justifications
This is perhaps the most underappreciated category of filing deficiency, and it affects experienced regulatory teams as much as junior professionals. FDA does not simply want data. FDA wants interpreted data, with justifications that explain why the data supports the proposed specification, the proposed shelf life, the proposed manufacturing process, or the proposed biowaiver.
Justification failures take many forms:
Specification limits set without statistical or scientific basis: Proposed acceptance criteria that appear arbitrary, are more permissive than the RLD without justification, or are tighter than they need to be without explanation, all raise questions during filing review.
Dissolution specification not adequately justified: The dissolution method and acceptance criteria must be shown to be discriminating, relevant to the in vivo performance of the product, and developed in alignment with FDA's dissolution database and, where applicable, the PSG recommendations.
Process parameter ranges unjustified: In Module 3.2.P.3, the applicant must define the manufacturing process with validated or justified parameter ranges. Applications that list parameters without demonstrating how those ranges were selected, or without reference to development or process validation data, are incomplete.
Cross module inconsistencies: A particularly damaging form of deficiency is internal inconsistency, where the batch formula in 3.2.P.1 does not match the batch records referenced in 3.2.P.3.4, or the analytical method in 3.2.P.5.2 differs from the method used in stability studies in 3.2.P.8. These inconsistencies signal poor quality review of the application before submission.
Proactive Strategies That Actually Work
Strategy 1: Conduct a Mock Filing Review Before Submission
Every regulatory operations team of meaningful scale should conduct an internal mock filing review, modeled on FDA's own filing review checklist (Form FDA 3774 for ANDAs), before finalizing the submission package. This mock review should be conducted by a team member who was not involved in assembling the specific module being reviewed, simulating the independent eye of a DFR reviewer.
The mock review should cross-check every cross-reference, verify that every LOA is current, confirm that every analytical method cited in the specifications section is validated and that the validation report is included, and ensure that every batch referenced in stability tables matches the batch manufacturing records.
Strategy 2: Use FDA Controlled Correspondence Proactively
Under GDUFA II and GDUFA III commitments, FDA has established Controlled Correspondence as the formal mechanism for pre-submission scientific communication. Regulatory teams should use this mechanism strategically, particularly for complex products, products with special dosage forms (modified release, topical semisolids, inhalation, etc.), products requiring complex BE studies, and products where the PSG may be ambiguous or absent.
Controlled Correspondence responses from FDA carry significant weight. When an ANDA submission is aligned with a prior Controlled Correspondence response, the chances of RTR and major deficiency are substantially reduced.
Strategy 3: Align With Current PSGs and the FDA Dissolution Database
FDA's Office of Generic Drugs publishes product-specific guidances that are the single most authoritative source for ANDA preparation strategy for any given drug product. These guidances are regularly updated. A PSG that was current two years ago may have been revised to incorporate new dissolution testing requirements, updated BE study design recommendations, or additional in vitro data requirements.
Similarly, the FDA Dissolution Methods Database provides recommended dissolution test conditions that, when followed, significantly strengthen Module 3.2.P.5 and 3.2.P.8.
Strategy 4: Build a Submission Readiness Checklist Against eCTD Structure
The eCTD structure is not merely a formatting requirement. It is a logical organization framework that maps directly to FDA's review workflow. Applications where sections are missing, files are incorrectly hyperlinked, or documents are placed in the wrong module create a poor first impression during filing review and can contribute to RTR decisions even when the underlying science is sound.
Regulatory teams should maintain a master submission readiness checklist that maps every required document to its eCTD location, tracks the status of each document (in progress, in review, finalized, QC complete), and is signed off by at least two qualified regulatory professionals before submission.
Strategy 5: Invest in ICH Q10 Pharmaceutical Quality System Infrastructure
At the organizational level, the single most powerful predictor of ANDA filing quality is the strength of the pharmaceutical quality system (PQS) that governs dossier preparation. Organizations that have implemented ICH Q10-aligned PQS frameworks, with robust document control, change management, deviation management, and CAPA systems, consistently produce higher quality ANDA submissions.
This is particularly relevant for companies scaling from a small portfolio to a large generic pipeline, where the volume and complexity of simultaneous submissions creates significant risk of documentation gaps and cross-module inconsistencies.
A Note on the Role of Senior Regulatory Leadership
For directors, VPs, and heads of regulatory affairs, the insights from FDA's Generic Drugs Forum are not merely operational guidance for their teams. They are strategic signals about where FDA's enforcement focus is sharpening.
The growing complexity of generic drug development, including complex drug substances, complex formulations, complex routes of administration, and complex drug device combinations, means that the old playbook of assembling a dossier primarily from analytical data and BE study results is no longer sufficient. FDA expects a science-based development narrative that explains every decision from formulation design through commercial scale validation.
Senior regulatory leaders should ensure that:
Their teams have access to and are trained on the latest FDA PSGs, guidances, and Generic Drug Forum presentations.
Pre-submission scientific engagement with FDA through Controlled Correspondence is built into the project timeline, not treated as an afterthought.
The regulatory operations function has adequate resourcing for quality review of dossiers before submission, including dedicated QC review time that is protected from project timeline pressure.
DMF management, vendor qualification, and third-party analytical laboratory oversight are treated as regulatory functions, not just procurement or quality assurance functions.
Cross-functional ANDA readiness reviews involving regulatory, CMC, analytical, pharmacokinetics, and manufacturing teams are standard practice before any ANDA submission.
Conclusion: The Cost of Getting It Wrong vs. the Dividend of Getting It Right
A Refuse to Receive decision on an ANDA is not simply a paperwork setback. In a competitive generic market where first-to-file status under Paragraph IV certification can mean hundreds of millions of dollars in 180-day exclusivity, an RTR can permanently eliminate that competitive advantage. Even for non-paragraph IV products, delayed approval means delayed revenue, delayed patient access to affordable medicines, and a reputational signal to the broader organization that the regulatory function needs improvement.
The good news is that the vast majority of filing deficiencies are preventable. FDA has been remarkably transparent about what it expects, through PSGs, guidance documents, Generic Drug Forum presentations, and GDUFA public meetings. The professional who invests in understanding these expectations, who builds systematic processes around completeness and quality, and who engages FDA proactively as a scientific partner rather than reactively as a regulatory gatekeeper, will consistently outperform those who do not.
The standard has been clearly communicated. The question is whether regulatory teams are listening closely enough to act on it.
The Soutik covers regulatory science, pharmaceutical affairs, medical breakthroughs, and technology for professionals and curious minds. Follow for more.
0 Comments